# Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

> **NCT00851227** · PHASE1 · COMPLETED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 26 (actual)

## Conditions studied

- Liver Disease
- Hyponatremia

## Interventions

- **DRUG:** conivaptan hydrochloride

## Key facts

- **NCT ID:** NCT00851227
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2014-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00851227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00851227, "Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00851227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*